

# Nanostructured Drug-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/N357C61F98BEN.html>

Date: February 2018

Pages: 130

Price: US\$ 3,480.00 (Single User License)

ID: N357C61F98BEN

## Abstracts

### Report Summary

Nanostructured Drug-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Nanostructured Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Nanostructured Drug 2013-2017, and development forecast 2018-2023

Main market players of Nanostructured Drug in Europe, with company and product introduction, position in the Nanostructured Drug market

Market status and development trend of Nanostructured Drug by types and applications

Cost and profit status of Nanostructured Drug, and marketing status

Market growth drivers and challenges

The report segments the Europe Nanostructured Drug market as:

Europe Nanostructured Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Nanostructured Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Liposomes

Polymeric Micelles

Solid lipid Nanoparticles

Microemulsion and Nanoemulsion

Nanosuspension

Europe Nanostructured Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Cancer and Tumors

Autoimmune Disorders

Europe Nanostructured Drug Market: Players Segment Analysis (Company and Product introduction, Nanostructured Drug Sales Volume, Revenue, Price and Gross Margin):

Merck

Pfizer

Novartis

Abbott

GlaxoSmithKline

Roche

Sanofi

Eli Lilly

Astrazeneca

Johnson & Johnson

Celgene

Novavax

Stryker

Gilead Sciences

OSI Pharmaceuticals

Kadmon Pharmaceuticals

Samyang Biopharm

Mitsubishi Pharma?

Kaken Pharmaceutical  
Selecta Biosciences  
Par Pharmaceutical  
Cerulean Pharma  
Navidea Biopharmaceuticals  
Lummy

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF NANOSTRUCTURED DRUG**

- 1.1 Definition of Nanostructured Drug in This Report
- 1.2 Commercial Types of Nanostructured Drug
  - 1.2.1 Liposomes
  - 1.2.2 Polymeric Micelles
  - 1.2.3 Solid lipid Nanoparticles
  - 1.2.4 Microemulsion and Nanoemulsion
  - 1.2.5 Nanosuspension
- 1.3 Downstream Application of Nanostructured Drug
  - 1.3.1 Cancer and Tumors
  - 1.3.2 Autoimmune Disorders
- 1.4 Development History of Nanostructured Drug
- 1.5 Market Status and Trend of Nanostructured Drug 2013-2023
  - 1.5.1 Europe Nanostructured Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Nanostructured Drug Market Status and Trend 2013-2023

### **CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Nanostructured Drug in Europe 2013-2017
- 2.2 Consumption Market of Nanostructured Drug in Europe by Regions
  - 2.2.1 Consumption Volume of Nanostructured Drug in Europe by Regions
  - 2.2.2 Revenue of Nanostructured Drug in Europe by Regions
- 2.3 Market Analysis of Nanostructured Drug in Europe by Regions
  - 2.3.1 Market Analysis of Nanostructured Drug in Germany 2013-2017
  - 2.3.2 Market Analysis of Nanostructured Drug in United Kingdom 2013-2017
  - 2.3.3 Market Analysis of Nanostructured Drug in France 2013-2017
  - 2.3.4 Market Analysis of Nanostructured Drug in Italy 2013-2017
  - 2.3.5 Market Analysis of Nanostructured Drug in Spain 2013-2017
  - 2.3.6 Market Analysis of Nanostructured Drug in Benelux 2013-2017
  - 2.3.7 Market Analysis of Nanostructured Drug in Russia 2013-2017
- 2.4 Market Development Forecast of Nanostructured Drug in Europe 2018-2023
  - 2.4.1 Market Development Forecast of Nanostructured Drug in Europe 2018-2023
  - 2.4.2 Market Development Forecast of Nanostructured Drug by Regions 2018-2023

### **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole Europe Market Status by Types
  - 3.1.1 Consumption Volume of Nanostructured Drug in Europe by Types
  - 3.1.2 Revenue of Nanostructured Drug in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Germany
  - 3.2.2 Market Status by Types in United Kingdom
  - 3.2.3 Market Status by Types in France
  - 3.2.4 Market Status by Types in Italy
  - 3.2.5 Market Status by Types in Spain
  - 3.2.6 Market Status by Types in Benelux
  - 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Nanostructured Drug in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Nanostructured Drug in Europe by Downstream Industry
- 4.2 Demand Volume of Nanostructured Drug by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Nanostructured Drug by Downstream Industry in Germany
  - 4.2.2 Demand Volume of Nanostructured Drug by Downstream Industry in United Kingdom
  - 4.2.3 Demand Volume of Nanostructured Drug by Downstream Industry in France
  - 4.2.4 Demand Volume of Nanostructured Drug by Downstream Industry in Italy
  - 4.2.5 Demand Volume of Nanostructured Drug by Downstream Industry in Spain
  - 4.2.6 Demand Volume of Nanostructured Drug by Downstream Industry in Benelux
  - 4.2.7 Demand Volume of Nanostructured Drug by Downstream Industry in Russia
- 4.3 Market Forecast of Nanostructured Drug in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF NANOSTRUCTURED DRUG**

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Nanostructured Drug Downstream Industry Situation and Trend Overview

## **CHAPTER 6 NANOSTRUCTURED DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

- 6.1 Sales Volume of Nanostructured Drug in Europe by Major Players

- 6.2 Revenue of Nanostructured Drug in Europe by Major Players
- 6.3 Basic Information of Nanostructured Drug by Major Players
  - 6.3.1 Headquarters Location and Established Time of Nanostructured Drug Major Players
  - 6.3.2 Employees and Revenue Level of Nanostructured Drug Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 NANOSTRUCTURED DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Merck
  - 7.1.1 Company profile
  - 7.1.2 Representative Nanostructured Drug Product
  - 7.1.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Merck
- 7.2 Pfizer
  - 7.2.1 Company profile
  - 7.2.2 Representative Nanostructured Drug Product
  - 7.2.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Pfizer
- 7.3 Novartis
  - 7.3.1 Company profile
  - 7.3.2 Representative Nanostructured Drug Product
  - 7.3.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Novartis
- 7.4 Abbott
  - 7.4.1 Company profile
  - 7.4.2 Representative Nanostructured Drug Product
  - 7.4.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Abbott
- 7.5 GlaxoSmithKline
  - 7.5.1 Company profile
  - 7.5.2 Representative Nanostructured Drug Product
  - 7.5.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.6 Roche
  - 7.6.1 Company profile
  - 7.6.2 Representative Nanostructured Drug Product
  - 7.6.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Roche
- 7.7 Sanofi

- 7.7.1 Company profile
- 7.7.2 Representative Nanostructured Drug Product
- 7.7.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Sanofi
- 7.8 Eli Lilly
  - 7.8.1 Company profile
  - 7.8.2 Representative Nanostructured Drug Product
  - 7.8.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.9 Astrazeneca
  - 7.9.1 Company profile
  - 7.9.2 Representative Nanostructured Drug Product
  - 7.9.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Astrazeneca
- 7.10 Johnson & Johnson
  - 7.10.1 Company profile
  - 7.10.2 Representative Nanostructured Drug Product
  - 7.10.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.11 Celgene
  - 7.11.1 Company profile
  - 7.11.2 Representative Nanostructured Drug Product
  - 7.11.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Celgene
- 7.12 Novavax
  - 7.12.1 Company profile
  - 7.12.2 Representative Nanostructured Drug Product
  - 7.12.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Novavax
- 7.13 Stryker
  - 7.13.1 Company profile
  - 7.13.2 Representative Nanostructured Drug Product
  - 7.13.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Stryker
- 7.14 Gilead Sciences
  - 7.14.1 Company profile
  - 7.14.2 Representative Nanostructured Drug Product
  - 7.14.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of Gilead Sciences
- 7.15 OSI Pharmaceuticals
  - 7.15.1 Company profile
  - 7.15.2 Representative Nanostructured Drug Product
  - 7.15.3 Nanostructured Drug Sales, Revenue, Price and Gross Margin of OSI Pharmaceuticals
- 7.16 Kadmon Pharmaceuticals

- 7.17 Samyang Biopharm
- 7.18 Mitsubishi Pharma?
- 7.19 Kaken Pharmaceutical
- 7.20 Selecta Biosciences
- 7.21 Par Pharmaceutical
- 7.22 Cerulean Pharma
- 7.23 Navidea Biopharmaceuticals
- 7.24 Lummy

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF NANOSTRUCTURED DRUG**

- 8.1 Industry Chain of Nanostructured Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF NANOSTRUCTURED DRUG**

- 9.1 Cost Structure Analysis of Nanostructured Drug
- 9.2 Raw Materials Cost Analysis of Nanostructured Drug
- 9.3 Labor Cost Analysis of Nanostructured Drug
- 9.4 Manufacturing Expenses Analysis of Nanostructured Drug

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF NANOSTRUCTURED DRUG**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**



## 12.1 Methodology/Research Approach

### 12.1.1 Research Programs/Design

### 12.1.2 Market Size Estimation

### 12.1.3 Market Breakdown and Data Triangulation

## 12.2 Data Source

### 12.2.1 Secondary Sources

### 12.2.2 Primary Sources

## 12.3 Reference

## I would like to order

Product name: Nanostructured Drug-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/N357C61F98BEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N357C61F98BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970